Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252413264 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Razia Aslam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Group, Department of Medicine, RCSI University of Medicine and Health Sciences, D09 YD60 Dublin, Ireland. Hauptthemen laut MEDLINE: Purines, Aminopyridines, Colorectal Neoplasms, Drug Synergism. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: North East Cancer Research and Education Trust, St Luke's Institute of Cancer Research, RCSI StAR MD Programme.
Abstract (Originalsprache)
The CDK4/6 inhibitor Ribociclib has shown limited efficacy as a monotherapy in colorectal cancer (CRC). However, combining Ribociclib with targeted therapies could present a viable strategy for treating CRC. This study evaluated the combination of Ribociclib and the PI3K inhibitor Alpelisib across four distinct cell lines representing different mutational statuses (PIK3CA/KRAS wild-type, KRAS-mutated, PIK3CA-mutated, and PIK3CA/KRAS-mutated). We analyzed the drugs’ impact on key proteins involved in the PI3K pathway, cell cycle regulation, and apoptosis. The combination of Alpelisib and Ribociclib demonstrated a synergistic anti-proliferative effect across all cell lines, leading to a simultaneous decrease in pRB, pAKT, and p-S6 levels, and a more comprehensive suppression of the PI3K/AKT/mTOR pathway. Additionally, there was an upregulation of the apoptotic marker, p-BCL2, in cells treated with the combination compared to controls. In vivo studies using Caco-2, LS1034, and SNUC4 xenografts revealed a significant reduction in tumour growth with the combination therapy compared to single-agent treatments. These findings suggest that combining Alpelisib and Ribociclib could be a promising therapeutic approach for CRC, warranting further clinical exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Group, Department of Medicine, RCSI University of Medicine and Health Sciences, D09 YD60 Dublin, Ireland.
- Beaumont RCSI Cancer Centre, D09 YD60 Dublin, Ireland.
- Department of Medical Oncology, St James's Hospital, D08 NHY1 Dublin, Ireland.
- RCSI Biobank, RCSI University of Medicine and Health Sciences, D09 YD60 Dublin, Ireland.
- Department of Pathology, RCSI University of Medicine and Health Science, D09 YD60 Dublin, Ireland.
- Department of Surgery, RCSI University of Medicine and Health Science, D09 YD60 Dublin, Ireland.
ORCID-Profile: Joanna Fay, Julie Workman
Förderung
- North East Cancer Research and Education Trust
- St Luke's Institute of Cancer Research
- RCSI StAR MD Programme
- Luke’s Institute of Cancer Research (SLICR)
- RCSI/Hermitage Clinic StAR MD Programme
Zitieren
APA
Aslam, R., Richards, C. E., Fay, J., Hudson, L., Workman, J., Lee, C. L., Murphy, A., O'Neill, B., Toomey, S., & Hennessy, B. T. (2024). Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413264
Vancouver
Aslam R, Richards CE, Fay J, Hudson L, Workman J, Lee CL, et al. Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413264
BibTeX
@article{Aslam2024,
author = {Aslam, Razia and Richards, Cathy E and Fay, Joanna and Hudson, Lance and Workman, Julie and Lee, Cha Len and Murphy, Adrian and O'Neill, Brian and Toomey, Sinead and Hennessy, Bryan T},
title = {Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252413264}
}
EUVIMED